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ABSTRACT
In a two-stage phase II study, 24 patients with ﬁrst diagnosis of glioblastoma (GBM) were treated with
dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ)
followed by adjuvant TMZ.
Three intradermal injections of mature DC loaded with autologous GBM lysate were administered
before adjuvant TMZ, while 4 injections were performed during adjuvant TMZ. According to a two-
stage Simon design, to proceed to the second stage progression-free survival (PFS) 12 months after
surgery was expected in at least 8 cases enrolled in the ﬁrst stage. Evidence of immune response
and interaction with chemotherapy were investigated. After a median follow up of 17.4 months, 9
patients reached PFS12. In these patients (responders, 37.5%), DC vaccination induced a signiﬁcant,
persistent activation of NK cells, whose increased response was signiﬁcantly associated with
prolonged survival. CD8C T cells underwent rapid expansion and priming but, after the ﬁrst
administration of adjuvant TMZ, failed to generate a memory status. Resistance to TMZ was
associated with robust expression of the multidrug resistance protein ABCC3 in NK but not CD8C T
cells. The negative effect of TMZ on the formation of T cell-associated antitumor memory deserves
consideration in future clinical trials including immunotherapy.
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Introduction
Immunotherapy with dendritic cells (DC) has not yet fulﬁlled
the promise for cancer treatment. Even if DC vaccinations have
scarce toxicity and serious adverse events were not reported,
clinical relevance has been hampered by the limited translation
of immune activation into clinical response.1,2
The observation that chemotherapeutic agents like anthra-
cyclines may exert immunostimulatory effects has generated
new expectations for DC immunotherapy of cancer.3-5
Clinical data on the combination of temozolomide (TMZ),
with immunotherapy are limited. In vitro results suggest that
TMZ, the standard chemotherapy in glioblastoma (GBM), reduces
expression of the T regulatory (Treg) cell attractant CCL2 in GBM
cells.6,7 In one patient TMZ-induced lymphopenia was synergistic
with a peptide vaccine, possibly because of Treg inhibition.8 In a
rat model of GBM, TMZ depletes Treg cells using a “metronomic”
schedule, and metronomic cyclophosphamide favors anti-glioma
CD8C T cell responses.9,10 Recent data in the mouse model
GL261, however, showed that alkylating chemotherapy with a
schedule resembling standard rather than metronomic treatment,
impairs adaptive immune responses.11
Overall, clinical data on the combination of TMZ and DC
immunotherapy are lacking. Here we report the results of the
ﬁrst stage of DENDR1 (EUDRACT N 2008-005035-15), a
phase II, uncontrolled, open label, nonrandomized study in
patients with ﬁrst diagnosis of GBM in which DC immunother-
apy is associated with standard radiotherapy and chemotherapy
with TMZ.
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Results
Patient treatment and survival. The schedule of the treatment
and clinical features of the 24 patients are summarized in
Fig. 1A and Table 1. Sixteen patients completed all scheduled
vaccinations; 7 discontinued TMZ and immunotherapy after at
least 4 vaccinations because of disease progression; one patient
received 6 vaccinations, experienced severe pulmonary embo-
lism and withdrew his consent to immunotherapy.
Twenty-two patients underwent recurrence, one died
because of heart failure before progression (Pt 3) and one was
still progression-free at the time of the analysis (Pt 23). Six
patients with recurrence did not receive any treatment because
of severe clinical worsening (Pts 5, 11, 18 and 19), while two
Figure 1. Survival analysis of 24 GBM patients treated by DC immunotherapy. (A) Treatment protocol showing the timing before, during and after the DC administrations.
D D day, W D week, White circle D MRI, Black diamond: clinical monitoring, White square D immune monitoring except DTH, DCn D vaccine number, Gray rectangle D
maintenance TMZ (5 days/28 for 6 cycles). (B) Kaplan Meier curves showing progression free survival (PFS) and (C) overall survival (OS) of the 24 patients enrolled in the
ﬁrst stage of DENDR1. Kaplan Meier curves showing PFS (D) and OS (E) of patients, with methylated or unmethylated MGMT promoter in the tumor.
Table 1. Patient characteristics.
Patient Age/Gender
KPS
post-surgery
Steroids at 1st
vaccination (mg)
No. of
vaccinations
No. of
TMZ cycles
MGMT
(Met0.1)
NK cell
V/B ratio
PFS
(mts)
OS
(mts)
Treatment
after IT
1 55/F 100 0.00 7 6 U (0.07) 0.7 13.7 22.5 No treatment
2 62/F 100 1.25 7 5 U (0.01) 0.7 12.0 24.4 Bevacizumab
3 66/M 80 0.00 7 6 U (0.04) 2.8 15.4 15.4 No treatment
4 70/F 80 0.00 7 6 U (0.00) 1.3 14.7 17.8 Bevacizumab
5 49/M 90 0.00 7 6 U (0.00) 1.7 10.2 12.5 No treatment
6 65/F 70 4.00 7 6 M (0.71) 3.0 20.8 33.9 Metronomic TMZ
7 60/M 80 0.00 7 6 U (0.01) 1.7 9.3 25.0 Bevacizumab
8 58/M 100 2.00 7 6 U (0.00) 2.2 9.4 22.6 Bevacizumab
9 50/M 90 0.00 7 6 U (0.00) 5.0 16.1 33.0 TMZ, Cyber, PCV
10 48/M 80 2.00 3 2 M (2.83) 4.0 4.4 7.8 Bevacizumab
11 23/F 90 0.00 4 1 U (0.003) 0.7 3.1 6.4 No treatment
12 44/M 70 0.00 7 6 U (0.03) 2.8 24.2 38.4 PCV
13 55/M 70 4.00 6 6 U (0.00) 1.9 10.7 19.4 No treatment
14 62/M 80 0.00 7 6 M (0.46) 0.7 7.9 20.2 Bevacizumb
15 36/M 100 2.00 5 2 U (0.00) 3.2 2.9 19.9 RT
16 70/M 80 4.00 7 6 M (1.50) 2.9 17.2 32.8 CCNU
17 56/F 80 4.00 4 1 U (0.00) 1.5 3.0 11.9 Bevacizumab
18 49/M 80 4.00 4 2 U (0.00) 2.1 6.3 8.8 No treatment
19 56/M 70 4.00 4 1 U (0.02) 0.6 3.2 6.9 No treatment
20 48/M 70 4.00 5 6 U (0.00) 0.6 9.0 12.4 CCNU
21 53/F 90 0.00 7 5 M (0.47) 5.0 28.3 >39.3 TMZ,PCV
22 63/M 90 4.00 5 3 U (0.02) 3.4 6.5 8.1 Bevacizumab
23 45/M 90 0.00 7 6 M (0.74) 2.7 >33.0 >33.0 No treatment
24 55/F 80 0.00 7 6 U (0.00) 3.2 14.0 28.3 Fotemustine
Abbreviations. KPS: Karnofsky performance status; TMZ: temozolomide; MGMT: O6-methylguanine-DNA-methyltransferase; PFS: progression free survival; OS: overall sur-
vival; PCV: Procarbazine, Lomustine, and Vincristine
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were lost to follow-up (Pts 1 and 13). Eight of the other 16
patients had second surgery. Other treatments included bevaci-
zumab (eight cases), chemotherapy (six cases), cyber-knife plus
chemotherapy (one case) and radiotherapy (one case) (Table 1).
Median follow up was 17.4 months, median PFS was 10.5
months (95% CI 9.15–15.44), PFS6 was 79% and PFS12 41%
(Fig. 1 B). Nine patients were free from progression at 12
months, thus satisfying the criteria we had set for passage from
stage I to stage II of the Simon12 design employed in this study.
Here, for brevity and clarity we deﬁned them as responders
which does not imply that all nine had evidence of response to
immunotherapy.
Two of 24 patients were alive at the time of analysis: median
OS was 20.1 months (95% CI: 12.5–25), OS at 12 and 24
months were 75% and 37%, respectively (Fig. 1 C).
Disease progression was suspected for 5 patients (Pts 10, 11,
15, 17, 19) based on MRI performed one week after the end of
concomitant radiochemotherapy. These ﬁve patients were
treated and included in survival analysis: as the following MRI
conﬁrmed progression, the time of disease progression was
back-dated to previous MRI. Hypermethylation of the MGMT
promoter, present in 25% of patients (4 responders and 2 non-
responders), was the only clinical feature associated with longer
PFS and OS (P D 0.02 and P D 0.03 respectively). The median
PFS was 17.2 months (CI 95% 7.9–28.3) in the presence of
MGMT methylation and 10.2 months in the other cases (CI
95% 7.9–14.7) (Fig. 1D). The median OS was 32.8 months
(95%CI 20.2–33.9) in patients with MGMT methylation and
17.8 months in the others (CI 95% 14.4–22.6) (Fig. 1E). Exem-
pliﬁcative MRI of one responder and one non-responder
(patients number 12 and 17, respectively) are shown in Fig. 2.
Vaccine safety and adverse events. Three intradermal
injections of mature DC loaded with autologous whole
tumor lysate were administered before adjuvant TMZ, 4
further injections were performed during adjuvant TMZ
(Fig. 1A). The treatment was well tolerated. One patient
stopped treatment before disease progression due to pulmo-
nary embolism. One patient died before progression because
of deep venous thrombosis and pulmonary embolism. One
case of grade 5 disseminated intravascular coagulation
(DIC) was reported.
Five cases of partial seizures, 8 convulsions and 1 myositis
were also recorded. Non-serious skin reactions included itch-
ing, erythema, urticaria and temporary inﬂammation at the
injection site. A list of adverse events occurred during immuno-
therapy with relative grades is provided in Table S1.
Figure 2. Exempliﬁcative MRI. Patient 17. Top, T2 weighted images (w.i.); bottom, contrast enhanced T1 w.i. (small box, pre-contrast T1 w.i.). (A) Pre-surgery, Dec 5, 2012
(necrotic lesion, GBM). (B). Post-surgery: Dec 6, 2012 (blood presence). (C-E) Immunotherapy: Jan, Mar and May 2013 (progressively enhancing lesion). Patient 12. Top,
T2 w.i., bottom, contrast-enhanced T1 w.i. (F) Pre-surgery May 14, 2012 (necrotic lesion, GBM). (G) Post-surgery May 18, 2012 (scarce blood). (H-O) Immunotherapy: H-L
(Aug 2012, Nov 2012, Jan 2013) show enhancing lesion. (M) subsequently reduced (M, Mar 2013) suggesting pseudoprogression. (N) subsequent stabilization (May 2014).
(O) and disease progression (July 2014).
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Radio-chemotherapy and adjuvant chemotherapy affect
CD8C T, CD4C T and NK cell counts. TMZ-induced lympho-
depletion has been associated with expansion of a speciﬁc anti-
tumor immune response.13 We measured the absolute lympho-
cyte counts (ALCs) at leukapheresis (the basal time point), dur-
ing and at the end of the treatment. Basal ALCs were > 1,000
cells per mL peripheral blood in 22/24 patients at leukapheresis,
and dropped signiﬁcantly after RT-TMZ (from 1710.9 § 753.9
to 726.0 § 276.3, P < 0.0001) (Fig. 3A). RT-TMZ induced sig-
niﬁcant lymphopenia (<1000 lymphocytes/microl) in 19/24
patients (79%). In 6/19 patients, the ALCs were < 500 after
RT-TMZ.
RT-TMZ decreased CD8C T cell (499.8 § 318.9 before RT-
TMZ to 279.9 § 165.4, P D 0.004), CD4C T cell (from 708.0 §
371.8 to 312.6 § 107.7, P < 0.0005) and NK cell counts (from
88.0 § 72.9 to 45.7 § 37.9, P D 0.02) (Fig. 3B-D).
We also investigated the absolute count of CD8C T,
CD4C T and NK cell subsets in the peripheral blood of all
patients before, during and after immunotherapy. The
CD8C T cell subset of responders only increased early after
the second and third vaccination, but decreased in combi-
nation with adjuvant TMZ (Fig. 3E). CD4C T cell counts
did not increase during vaccinations (Fig. 3F). On the con-
trary, the NK cell subset of responders increased
Figure 3. Radiotherapy and chemotherapy impact on CD8C, CD4C T and NK cell counts. (A) Absolute lymphocyte counts in the peripheral blood of patients before (leuka-
pheresisD leuka) and after (ﬁrst vaccinationD I vacc) RT-TMZ. (B-D) CD8C, CD4C T and NK cell absolute counts before and after RT-TMZ. (E-G) Time course of CD8C T cell
count, CD4C T cell count and NK cell count measured by ﬂow cytometry of responder (left, n D 9) and non-responder (right, n D 15) patients over the treatment (P <
0.01, P < 0.005, P < 0.0005 vs. 1st vaccine; underlined asterisk  vs. leukapheresis). Data are presented as mean § SEM.
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signiﬁcantly after the third vaccination and remained con-
stant over time (Fig. 3G).
DC vaccines induce early NK cell activation followed by
CD4C T cells in a later phase. To investigate further the
immune responses induced by DC vaccinations, we correlated
counts and frequency of the 3 lymphocyte subsets with PFS and
OS. ROC curve analysis identiﬁed 2.2 as the vaccination/baseline
threshold (as deﬁned in METHODS, Statistical analyses) to dif-
ferentiate patients with high or low CD8C T, CD4C T and NK
cells (sensitivity 88.9%, speciﬁcity 80%). V/B ratios higher than
2.2 for NK but not for CD8C and CD4C T cell counts were asso-
ciated with prolonged PFS and OS (median PFS 16.1 months vs.
9.3 months, P D 0.002; median OS 32.8 months vs. 17.8 months,
P D 0.003) (Fig. 4A, B and Fig. S1A, B). This was conﬁrmed by
correlating survival data with NK, CD8C and CD4C T cell fre-
quencies (Fig. S1C-E). When the Bonferroni method was used
for multiple testing, the differences remained signiﬁcant (P D
0.016 for PFS and PD 0.024 for OS).
In order to investigate their independent prognostic role, a
multivariate analysis and a Cox proportional hazard regression
model analysis were performed on variables showing statisti-
cally signiﬁcant differences at univariate analysis (i.e. MGMT
methylation and V/B ratio for NK cell counts). Increased V/B
ratio for NK cell counts remained the only signiﬁcant predictor
of PFS (P D 0.02, exp(b) 0.24, 95% CI 0.071 – 0.85) and OS
(P D 0.03, exp(b)0.27, 95% CI 0.081–0.89).
To assess the speciﬁc anti-tumor immune responses induced
by DC vaccinations we measured IFN-g (Fig. 4C, D) and gran-
zyme-b (GZMB) (Fig. 4E, F) expression by intracellular staining
and ﬂow cytometry on NK and CD8C T cells in 11 patients (5
responders and 6 non-responders) with all blood specimens
available (Fig. 4C-D, Fig. S2A, B). After two DC vaccinations a
signiﬁcant expansion of NK cells expressing IFN-g in Peripheral
Blood Lymphocytes (PBLs) was detected in responders (P D
0.01 vs. leukapheresis; P D 0.02 vs. ﬁrst vaccine). After the third
vaccine NK cells continued to express higher levels of IFN-g in
response to and at the end of treatment (P D 0.004, responders
vs. non-responders). Notably, responders showed higher IFN-g
expression by NK cells and CD8C T cells already before RT-
TMZ (2.9§1.2 vs. 0.6§0.7; P D 0.01; 13.1§1.6 vs. 5.2§2.5; P D
0.008, respectively, responders vs. non-responders). IFN-g
expressing CD8C T cells in responders showed an early and sig-
niﬁcant expansion after the second vaccine, but a rapid depletion
after the fourth vaccine, concomitant with the ﬁrst cycle of adju-
vant TMZ. Responders showed a signiﬁcant higher percentage
of NK cells expressing GZMB at the second, ﬁfth and sixth
Figure 4. DC vaccination induces a signiﬁcant activation of NK cells correlated with an increased survival of patients. (A, B) Kaplan-Meier analysis of the correlation
between V/B ratio of NK cell counts with (A) PFS and OS (B). Median PFS of patients with high V/B ratio (> 2.2, nD 11) vs. low ( 2.2, nD 13): 16.1 months vs. 9.3 months
(P D 0.0025); median OS: 32.8 months vs. 17.8 months (P D 0.0039). (C-D) Time course of frequency of NK cells (C), CD8C T cells (D) expressing IFN-g measured by ﬂow
cytometry (P < 0.01, P < 0.005, P < 0.0005 vs. leukapheresis; underlined asterisk responders vs. non-responders). Representative dot plots are shown in Fig. S.2. (E,
F) Time course of frequency of NK cells (E), CD8C T cells CD4C T cells (F) expressing GZMB measured by ﬂow cytometry (G) Time course of CD4C T cells expressing IFN-g
measured by ﬂow cytometry. Data are presented as mean § SEM. (H-I) Time course of IFN- g secretion by PBLs from (H) 4 responders and (I) 4 non-responders, co-cul-
tured for 5 days in the presence of autologous loaded mature DC.
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vaccination (P D 0.03, P < 0.05, compared to leukapheresis)
(Fig. 4E). No expansion was assessed for GZMB expressing
CD8C T cells neither in responders nor in non-responders
(Fig. 4F).
Activated, IFN-g positive CD4C T cells showed a late but
signiﬁcant expansion after the fourth vaccine (P < 0.005 vs.
leukapheresis) (Fig. 4G, Fig. S2C). NK cells were also ana-
lyzed as CD56dim and CD56bright positive cells.14,15 The
CD56dim NK cell cytotoxic subset was signiﬁcantly increased
in responders and persisted at the end of the treatment
(Fig. S3). The assessment of NK, CD4C and CD8C T cells in
six patients treated with the standard Stupp regimen in the
FluoGlio study16 showed no signiﬁcant changes in their fre-
quency after radio-chemotherapy (Fig. S4) suggesting that
DC vaccinations induce NK cell activation. We also co-cul-
tured PBLs from 8 patients with mature DCs loaded with
tumor lysate. IFN-g production assessed by ELISA reﬂected
values measured by ﬂow cytometry in PBLs from responders,
with a signiﬁcant increase at third vaccination and decrease
at fourth vaccination, after onset of adjuvant TMZ (Fig. 4H).
No difference was found in non-responders (Fig. 4I). This
observation suggests a potential direct involvement of
speciﬁc anti-tumor effector cells producing IFN-g in
response to tumor antigens presented by the dendritic cells.
The results indicate that NK cells are critical immune effec-
tors during DC vaccination and suggest that they may synergize
with CD4C T cells in a later phase, activating a clinically effec-
tive immune response.
CD8C T cells fail to develop a memory status and NK cells
are intrinsically resistant to chemotherapy. To study further
the effects of adjuvant TMZ on CD8C T cells, we examined by
ﬂow cytometry the generation of CD8C T cell central memory
(TCM) and T effector memory (TEM) during and after treat-
ment (Fig. 5A, B).17 In responders the signiﬁcant increase of
the CD8C TEM, frequency at second vaccination (P D 0.01)
dropped permanently after adjuvant TMZ. We did not observe
modulation of the TCM status. In non-responders we did not
observe any signiﬁcant expansion in the frequency of CD8C
TEM and TCM during DC vaccines.
The poor contribution of CD8C T cells to anti-tumor
responses was partly compensated by strong and long-lasting
NK cell responses. In order to understand this persistency, we
investigated the potential involvement of the multidrug resis-
tance protein ABCC3, based on our preclinical evidence that
Figure 5. NK cells, but not CD8C T cells express and are resistant to chemotherapy. (A-B). Time course of CD8C T effector memory and central memory cells evaluated by
ﬂow cytometry on PBMCs from 5 responders (A) and 6 non-responders (B) (P < 0.005 vs. leukapheresis). (C) Time course of Abcc3 expression assessed by real-time PCR
on PBLs of 17 patients (8 responders and 9 non-responders). (D-F) Time course of NK cell, CD8C T cell and CD4C T cell frequency expressing ABCC3, assessed by ﬂow
cytometry (P < 0.01, P < 0.005, P < 0.0005 vs. leukapheresis, P D 0.02  underlined asterisk responders vs. non-responders). Data are presented as mean § SEM.
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the efﬂux activity of ABCC3 confers chemoresistance to NK
cells and protection from apoptotic cell death.18 Abcc3 expres-
sion, investigated by real-time PCR, was signiﬁcantly higher in
responders (n D 8) than non-responders (n D 9; P D 0.0005) at
the time of ﬁrst vaccination after standard radio-chemotherapy
(P D 0.02) and remained higher after concomitant vaccine and
TMZ administration (P < 0.01) (Fig. 5C). Using ﬂow cytome-
try, we found that ABCC3 was expressed by NK cells but not
by CD8C T lymphocytes also in PBLs from 3 healthy volunteers
(68.6 § 16.8 vs. 1.2 § 0.8, respectively; P D 0.0002, not shown).
We also veriﬁed that at the time of leukapheresis (i.e. before
radiochemotherapy), NK cells from responders displayed
higher basal expression of ABCC3 than non-responders (28.7
§ 29.6% vs. 15.8 § 17.6%, respectively; P D 0.02) (Fig. 5D).
Responders showed a further increase of ABCC3 after DC vac-
cinations and concomitant TMZ. In CD8C T lymphocytes basal
expression of ABCC3 was negligible (Fig. 5E) and in CD4C T
lymphocytes quite low (Fig. 5F).
These results demonstrate that adjuvant TMZ limits the
CD8C T cell response interfering with the memory status gen-
eration. ABCC3 plays a protective role against chemotherapy
potentiating NK cell response and activity.
Tumor inﬁltrating NK cells are associated with a down-
modulation of NK activating ligands expressed by tumor cells.
To investigate whether an immune inﬁltration was detectable in
specimens of patients who developed recurrence and underwent
second surgery, we characterized the tumor inﬁltrating lympho-
cytes (TILs). Specimens from Pt 8, 9, 10, 14 and 15 were ana-
lyzed for TILs by ﬂow cytometry (Fig. 6A and Fig. S5) and by
real time PCR for the expression of NK activating (MICA,
MICB, ULBP1-3) or inhibiting (HLA-E) ligands and receptors
(NKp30, NKp44, NKp46, NKp80, NKG2D) (Fig. 6 B-E). In three
cases (Pts 9, 10, 15) NK cell inﬁltration reﬂected the peripheral
NK cell response (V/B ratio>2.2). An impressive inﬁltration of
NK cells was found in Pt 9 (responder) (Fig. 6A). The expression
of NK ligands was totally lost, however, (Fig. 6C), a potential
cause of the lack of tumor growth control. A reduction of NK
activating ligands and receptors in second compared to ﬁrst sur-
gery specimen was also observed in Pt 15, showing a massive
NK cell inﬁltration (Fig. 6B, C). The second surgery of Pt10 was
characterized by the removal of two different tumor specimens.
The larger tumor mass showed the evolution from GBM to glio-
sarcoma with little immune inﬁltration, while the smaller frag-
ment was highly inﬁltrated by NK cells and expressed higher
levels of NK activating ligands and receptors compared to ﬁrst
surgery (Fig 6 B-E). CD8C and CD4C T cell inﬁltration for Pts 8,
9 and 15 are reported in Fig. S5. Pt 14 (non-responder) showed
absence of immune cell inﬁltration, no expression of NK
Figure 6. Tumor inﬁltrating NK cell activity was inﬂuenced by the expression of activating or inhibiting NK ligands and receptors. (A) Dot plots showing the percentage of
NK cells inﬁltrating tumor mass of four patients as evaluated by ﬂow cytometry. (B-E) Bar graphs showing the relative expression of activating (MICA, MICB, ULBP1-3) or
inhibiting (HLA-E) ligands and receptors (NKp30, NKp44, NKp46, NKp80, NKG2D) in specimens from ﬁrst and second surgery of ﬁve patients (four non-responders – Pts 8,
10, 14, 15 – and one responder – Pt9), evaluated by real time PCR. The relative expression of ligands and receptors was compared with that detected in normal brain tis-
sue (dotted line).
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activating ligands and receptors, but signiﬁcant up-regulation of
HLA-E in both specimens.
These results indicate that peripheral and local NK cell
response can be similar. However, the down-regulation of NK
activating ligands can jeopardize the local anti-tumor activity
of NK cells.
Discussion
Previously, we found that increased survival in patients with
recurrent GBM treated by DC immunotherapy was primarily
associated with tumor debulking and NK cell responses.19 In the
ﬁrst stage of this phase II study, DENDR1, survival data of
patients with primary GBMmet the criteria for passage to the sec-
ond stage of the Simon design. Data on OS were further analyzed
using model 3 of the EORTC nomogram to predict survival in
GBM patients taking into account MGMT methylation, Mini
Mental Score Examination and WHO performance status (17).
The actual OS in DENDR1 compared favorably with expected OS
(13.0 months; 95% CI 11.4–14.9). The expected OS was 66% at 12
months, and 23% at 24 months, PD 0.004.20
While our study was running another study at our Institu-
tion, FluoGlio, enrolled patients with primary GBM that had
surgery with intra-operatory use of ﬂuorescein to help deﬁning
tumor borders.16 Survival data in DENDR1 compare favorably
with FluoGlio (median PFS and OS 10.5 and 20.1 months in
DENDR1 and 7 and 12 months in FluoGlio).
Results also conﬁrmed the safety of DC immunotherapy.
One patient had fatal disseminated intravascular coagulation.
However, the timing (last vaccination two months before
death) and lack of data in the literature do not support the
involvement of DC immunotherapy in this severe adverse
event, while the natural history of malignant gliomas does
include coagulation disorders.21
DENDR1 demonstrates that the increase of NK cells in
peripheral blood after DC vaccinations is strongly associated
with prolonged survival. Previous work showed that DC have a
critical role in priming NK cells thanks to trans-presentation of
interleukin (IL)-15.22,23 NK cell collaboration with DC is criti-
cal to promote recruitment of effector CD8C T cells to the
tumor microenvironment,24 an interaction that is critically
dependent on IL-18 release.25,26 However, recent data in
murine models indicate that NK cells may also restrain sponta-
neous CD8C T cell priming through DC interaction mediated
by the PD-1-PD-L1 checkpoint.27 It is conceivable that such
inhibition also took place in our patients, suggesting that com-
bination with checkpoint inhibitors may boost the anti-tumor
efﬁcacy of DC immunotherapy.
Another constraint to the development of CD8C T cell anti-
tumor activity and memory is likely due to their exquisite sensi-
tivity to TMZ. We found that administration of adjuvant TMZ
exerts negative effects on CD8C T cell activation and in particu-
lar on the generation of immune memory and central mem-
ory.17 Long-term CD8C T cell responses were negligible not
only in non-responders but also in responders, even if their
pre-existing activation before RT-TMZ conﬁrmed that GBM
patients may exhibit tumor-speciﬁc CD8C T cells in peripheral
blood.28
Notably, results of DENDR1 conﬁrmed our preclinical
observation that the multidrug resistance protein ABCC3 is
up-regulated in NK but not in CD8C T cells during TMZ treat-
ment.18 The expression and activity of this transporter were ele-
ments supporting chemoresistance in breast and non-small cell
lung cancers but have not been fully appreciated as a tool of
chemoresistance in immune cells.29,30 As only a subset of
patients beneﬁts from chemo-immunotherapy combination,
our hypothesis is that ABCC3 represents a predictive marker of
resistance of NK cells to TMZ forecasting a robust and long-
lasting response associated to increased survival. This may be
of critical relevance, as suggested by data in rodent models
showing that intra-tumor but not systemic delivery of TMZ
supports a strong CD8C T cell-based immune response.31 In
these experiments and in others showing lack of CD8C T cell
activation, high dose TMZ was used (25–75 mg/kg).11,31 In the
presence of low dose TMZ (2.5 mg/kg) or metronomic sched-
ules, such activation was present.9,32,33 Metronomic TMZ could
be a viable option for combination with immunotherapy as it
has been already used in primary and recurrent GBM with
acceptable toxicity and some evidence of efﬁcacy.9,34
In conclusion, DENDR1 showed an encouraging gain in
patient survival in the absence of major toxicity. Such gain
appeared signiﬁcantly dependent on NK cell activation. To
complete such immune response with the contribution of
CD8CT cells, the schedule of TMZ administration should be
carefully re-evaluated.
Material and methods
Clinical study. A 2-phase Simon design was used for the clini-
cal study DENDR1 (EUDRACT N 2008-005035-15).12 The
primary goal was to evaluate progression free survival (PFS)
rate 12 months after surgery (PFS12). Assuming as primary
endpoint the percentage of PFS12 patients and an increase to
42% of the historical control rate of 27%,6 the alternative
hypothesis will be rejected at the end of the ﬁrst stage if the
PFS12 rate will be less than 8/24 treated patients. Safety, feasi-
bility and evidence of immune response are considered. The
clinical protocol was approved by local and national regulatory
authorities including Besta Ethical Committee, Istituto Superi-
ore di Sanita (ISS) and AIFA (Italian Medicine Agency), and is
sponsored by Istituto Neurologico Besta (see protocol as Sup-
plemental File).
Population and treatment Protocol. Twenty-four patients
with ﬁrst diagnosis of GBM and no IDH1-2 mutations were
enrolled after written informed consent, using the following
inclusion criteria: histologically proven GBM, age 18 and
70 years, no multifocal or sub-ependymal diffusion of the
tumor, residual tumor volume after surgery <10 ml, conﬁrmed
by postoperative Magnetic Resonance Imaging (MRI) assess-
ment, dexamethasone daily dose 4 mg during the 2 days prior
to leukapheresis, Karnofsky performance status (KPS) 70,
non-necrotic tissue for lysate preparation and DC loading 1
gr and stored in liquid nitrogen, absence of past or current
autoimmune disease. After surgery, patients underwent leuka-
pheresis and radiochemotherapy (RT-TMZ), according to the
Stupp protocol.6 DC were loaded with whole tumor lysate and
produced under Good Manufacturing Practices (GMP)
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conditions.19,35,36 On day 15 after surgery, leukapheresis and
basal clinical, radiological and immune testing were performed.
Delayed-Type Hypersensitivity (DTH) skin reactions, injecting
Ag puriﬁed tuberculin as control and 10 mg of inactivated
tumor lysate, were tested before and after vaccinations 1–4.
The ﬁrst 4 vaccinations with tumor lysate loaded DC were per-
formed every two weeks, from week 9 to 15. After the fourth
vaccine, MRI was performed. Vaccinations 5 and 6 were spaced
one month (week 19 and 23, respectively). The last vaccine
dose (the 7th) was on week 31. At each vaccine injection, clini-
cal and immune monitoring was performed. From the end of
immunotherapy on, MRI, clinical and immune monitoring
were continued every 2 months. The 1st, 5th, 6th and 7th vac-
cines contained 10 million DC; the 2nd, 3rd and 4th vaccines
5 million DC. Adjuvant TMZ started immediately after 3rd
vaccination and continued for 6 cycles (Fig 1A).
MRI and response evaluation. Patients underwent conven-
tional contrast enhanced MRI (see Supplementary Data for
detailed radiological protocol) within two days after surgery,
within two days before the ﬁrst vaccination, every two months,
or in case of clinical worsening. Tumor volumes were deter-
mined on the 3D post gadolinium T1 weighted images by man-
ually outlining the enhancing portion of the lesion in MRIcro
(http://www.mricro.com). To calculate the total enhancing vol-
ume of the tumor, the number of enhancing voxels was multi-
plied by the voxel size. Disease progression was deﬁned
according to RANO criteria.37
Immune monitoring. Immune monitoring was performed
on the whole blood of each patient before, during and after DC
vaccinations. The immune responses were assessed before the
treatment, after each vaccination and at the end of the treat-
ment until tumor recurrence. Eight patients were re-operated
(Pt 2, 8, 9, 10, 14, 15, 16, 24). No adequate/sufﬁcient material
was obtained from surgery of Pt 2 and 17; Pt 24 underwent sur-
gery in another institute. Tumor inﬁltrating immune cells were
isolated by tumor specimens obtained from Pt 8, 9, 10, 14 and
15 using human Tumor Dissociation Kit in combination with
GentleMACS (Miltenyi Biotec). Antibodies, staining for effec-
tor activation, memory status formation and real time PCR
protocols are reported in Supplementary Data.
Statistical analyses. The ratio of the mean of vaccinations
(2nd to 7th)/baseline values (V/B ratio) of absolute count and
frequency of NK cells, CD8C and CD4C T cells for each patient
was calculated, and the median of all of the observations was
used as the cut off value to separate patients into the “low” or
“high” groups. The threshold able to separate patients with
“low” or “high” V/B ratio and having the best sensitivity and
speciﬁcity, was deﬁned using Receiver Operating Characteristic
(ROC) curves. PFS was calculated from ﬁrst surgery until dis-
ease progression and death/last follow-up, if censored. Overall
Survival (OS) was calculated from surgery to death due to any
cause or last follow-up (censored). Kaplan-Meier analysis was
used to estimate PFS and OS. The log rank test assessed differ-
ences in progression or survival in patients with different
immunological or clinical parameters.
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